Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries
Weight-loss jabs such as Wegovy could be made for just $3 a month, according to new analysis, potentially making the treatment available to millions in poorer countries as patents expire.
More than a billion people live with obesity worldwide, with rates rising fast in lower-income nations as they shift to westernised diets and more sedentary lifestyles.
Continue reading...Why This Matters
A recent study suggests that the weight-loss jab semaglutide, found in medications like Ozempic and Wegovy, could be produced at a significantly lower cost, making it more accessible to millions worldwide, particularly in low-income countries.
In Week 10 2026, Science accounted for 15 related article(s), with UK Politics setting the broader headline context. Coverage of Science decreased by 5 article(s) versus the prior week, but remained material in the weekly agenda.
Coverage Snapshot
Week 10 2026 included 15 Science article(s). Leading outlets for this topic included NY Times, BBC, Guardian Business. Across that cluster, sentiment showed a mostly neutral skew (avg score 0.04).
Key Insights
Tone & Sentiment
The article tone is classified as positive, driven by the language and emphasis in the summary. The sentiment score of 0.16 indicates the strength of that tone.
Context
The study's findings align with growing concerns about the rising obesity rates in lower-income nations, where a shift towards westernized diets and sedentary lifestyles is contributing to a public health crisis. Media outlets have highlighted the potential for generic versions of semaglutide to address this issue, with some outlets emphasizing the need for increased access to affordable healthcare in developing countries. However, others have raised questions about the feasibility of large-scale production and distribution of generic versions.
Related Topics
Key Takeaway
In short, this article underscores key movement in Science and explains why it matters now.